ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO173

Coronary Calcification in Peritoneal Dialysis Patients: The Contribution of Traditional and Uremia-Related Risk Factors

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Gueiros, Ana Paula, Instituto de Medicina Integral Professor Fernando Figueira, Recife, Pernambuco, Brazil
  • Gueiros, Jose Edevanilson, Instituto de Medicina Integral Professor Fernando Figueira, Recife, Pernambuco, Brazil
  • Oliveira, Karina Tavares de melo nobrega de, Instituto de Medicina Integral Professor Fernando Figueira, Recife, Pernambuco, Brazil
  • Matta, Marina Cadena, Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Pernambuco, Brazil
  • Torres, Leuridan Cavalcante, Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Pernambuco, Brazil
  • Souza, Alex Sandro rolland, Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Pernambuco, Brazil
  • Casarini, Dulce Elena, Federal University of Sao Paulo, São Paulo, São Paulo, Brazil
  • Carvalho, Aluizio B., Federal University of Sao Paulo, São Paulo, São Paulo, Brazil
Background

Coronary calcification (CC) is commonly observed in dialysis patients and is associated with cardiovascular and all-cause mortality. Its pathogenesis is complex and involves a series of markers that interact in the vascular microenvironment. There are very few studies that assess the presence of CC in peritoneal dialysis (PD). The aim of this study was to evaluate the frequency and the factors associated with CC in PD patients.

Methods

A total of 81patients were enrolled. Coronary calcification was assessed using a multislice coronary tomography. Patients with a coronary calcium score (CCS) ≥ 30 Agatston units were considered as having CC. Demographic data were collected and the serum levels of biochemical and bone-derived biomarkers, including sclerostin and fetuin-A, were measured.

Results

Thirty-eight patients (47%) presented with CC. Calcified patients were older adults (p <0.001), presenting with more comorbidities, such as diabetes mellitus (p=0.043), dyslipidemia (p=0.040), and smoking (p=0.003)
Calcified patients presented higher serum levels of sclerostin (p=0.005). There was a tendency for calcified patients to have lower levels of fetuin-A (p = 0.05). In a multivariate logistic regression analysis, age, serum sclerostin level, and smoking were independently associated with CC. For each increase of 100 units in the serum level of sclerostin, there was a 13% increase in the likelihood of CC. CCS was positively correlated with age, time on PD, and serum sclerostin levels

Conclusion

Coronary calcification is highly prevalent in PD patients and is associated with older age, diabetes and smoking. Serum levels of sclerostin were independently associated with CC.